Micromedic Reports Success in Clinical Pilot of its Cervical Cancer Diagnostic Product in a Central Hospital in Beijing
Micromedic Technologies is expanding its penetration in the Chinese market.
The Company reported positive results in its pilot study conducted in Peking Union Medical College Hospital (Union Hospital), a central hospital in Beijing, using the CellDetect® product for the detection and identification of cervical cancer.
The Company also announced the receipt of a second significant order for the purchase of cervical cancer detection kits from its strategic partner in China, Biomics Co., comprising kit materials for approximately 100,000 tests. This follows the first commercial consignment that Micromedic sent to Biomics, containing kit materials for 20,000 tests.